| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Pharmacokinetics of the Institute of Bacteriology, 3, rue Koeberlé, [F. J., D. L., H. M.] and Department of Pneumology [E. Q., G. P.], University-Hospital Center, 67000 Strasbourg, and Pierre Fabre Medicaments, Paris [F. B., A. K.], France
The pharmacokinetics and metabolism of Navelbine (NVB) were investigated in 20 patients by a specific high performance liquid chromatographic methodology allowing the monitoring of NVB, deacetyl-NVB, and N-oxide NVB. After the i.v. (15 min) administration of 30 mg/m2 of drug, blood and urine samples were collected for, respectively, 144 and 48 h. NVB is characterized by a three compartmental kinetics, with a Cmax of 1130 ± 139 (SEM) ng/ml. The total body clearance and apparent volume of distribution, as defined by high performance liquid chromatography, are 1.26 ± 0.09 liter/h/kg (48.6 ± 4.1 liters/h/m2) and 75.6 ± 9.2 liters/kg (2918.4 ± 307.2 liters/m2). No metabolite could be detected in serum; the urinary excretion of NVB represented 11% of the administered dose. Deacetyl-NVB could be identified as a minor urinary metabolite when no N-oxide NVB appeared in the urine samples. Two additional peaks appeared in most of urinary chromatograms as trace amounts. Thus, the major pathway of NVB, as for other Vinca alkaloids, should be hepatic clearance, as biliary elimination and/or hepatic biotransformation.
1 To whom requests for reprints should be addressed.
Received 11/ 9/90. Accepted 2/ 6/91.
This article has been cited by other articles:
|
|
 |
|
  D. Leveque and F. Jehl Molecular Pharmacokinetics of Catharanthus (Vinca) Alkaloids J. Clin. Pharmacol., May 1, 2007; 47(5): 579 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Evans, L. J. Jolivette, R. Nagilla, and K. W. Ward EXTRAPOLATION OF PRECLINICAL PHARMACOKINETICS AND MOLECULAR FEATURE ANALYSIS OF "DISCOVERY-LIKE" MOLECULES TO PREDICT HUMAN PHARMACOKINETICS Drug Metab. Dispos., July 1, 2006; 34(7): 1255 - 1265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wong, R. L. Balleine, E. Y.L. Blair, A. J. McLachlan, S. P. Ackland, M. B. Garg, S. Evans, D. Farlow, M. Collins, L. P. Rivory, et al. Predictors of Vinorelbine Pharmacokinetics and Pharmacodynamics in Patients With Cancer J. Clin. Oncol., June 1, 2006; 24(16): 2448 - 2455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Johansen, J. Kuttesch, W. A. Bleyer, M. Krailo, M. Ames, and T. Madden Phase I Evaluation of Oral and Intravenous Vinorelbine in Pediatric Cancer Patients: A Report from the Children's Oncology Group Clin. Cancer Res., January 15, 2006; 12(2): 516 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Pegram, G. E. Konecny, C. O'Callaghan, M. Beryt, R. Pietras, and D. J. Slamon Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer J Natl Cancer Inst, May 19, 2004; 96(10): 739 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kajita, T. Kuwabara, H. Kobayashi, and S. Kobayashi CYP3A4 Is Mainly Responsibile for the Metabolism of a New Vinca Alkaloid, Vinorelbine, in Human Liver Microsomes Drug Metab. Dispos., September 1, 2000; 28(9): 1121 - 1127. [Abstract] [Full Text]
|
|
|
|
|
|
A. Gauvin, F. Pinguet, S. Culine, C. Astre, R. Gomeni, and F. Bressolle Bayesian Estimate of Vinorelbine Pharmacokinetic Parameters in Elderly Patients with Advanced Metastatic Cancer Clin. Cancer Res., July 1, 2000; 6(7): 2690 - 2695. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
